Abstract: BACKGROUND We investigated the prognostic significance of B-cell differentiation status and common B-cell differentiation markers in a post hoc analysis of 119 patients with primary CNS lymphoma (PCNSL) homogeneously receiving high-dose methotrexate (HDMTX)-based chemotherapy within the prospective G-PCNSL-SG1 trial. METHODS We evaluated protein expression of B-cell lymphoma 2 (BCL2), BCL6, CD10, and multiple myeloma oncogene 1/interferon regulatory factor 4 (MUM1/IRF4) by immunohistochemistry and analyzed the association with survival. RESULTS The median follow-up of all patients was 67.5 months. Median progression-free survival (PFS) was 10.61 months (95% CI: 4.23-17.00). Median overall survival (OS) was 28.85 months (95% CI: 17.96-39.73). Eighty-nine tumors expressed BCL2 (92.7%), 24 (20.5%) expressed CD10, 60 (54.1%) expressed BCL6, and 87 (79.0%) expressed MUM1/IRF4. On the basis of the Hans algorithm, 80 tumors (73.4%) were classified to the non-germinal center B group, suggesting a post-germinal center origin of PCNSL. Expression of BCL6 (cutoff point 30%), but none of the other markers, was associated with shorter PFS (P = .047) and OS (P = .035). On multivariate analysis, BCL6 expression was associated with shorter PFS (hazard ratio: 1.95, 95% CI: 1.22-3.12, P = .005) but not OS (hazard ratio: 1.85, 95% CI: 0.71-4.80, P = .21). Classification according to Hans algorithm and expression status of the single B-cell markers BCL2, CD10, and MUM1/IRF4 did not correlate with prognosis. CONCLUSION The findings are limited by the fact that only 23% of all G-PCNSL-SG1 patients could be included in the analysis. If validated in an independent cohort, BCL6 may assume clinical relevance as an unfavorable prognostic biomarker in PCNSL.
Introduction
Primary CNS lymphoma (PCNSL) is a rare aggressive B cell neoplasia most frequently of diffuse large B cell lymphoma type (DLBCL) that is confined to the CNS at time of diagnosis 1 . The formerly poor prognosis of PCNSL has been greatly improved by systemic high-dose methotrexate (HDMTX)-based polychemotherapy which provides the current standard treatment for all patients with PCNSL. Despite substantial improvements in the treatment of PCNSL the response to HDMTX-based chemotherapy is quite heterogeneous and overall prognosis remains poor with a median progression-free survival (PFS) of approximately 12 months and a median overall survival (OS) of about 3 years in most studies.
This necessitates the identification and evaluation of reliable predictive and prognostic biomarkers for risk-stratified treatment decisions 2 .
In systemic DLBCL, prognostic value of different biologic markers has widely been studied.
Moreover, at least two prognostically important subgroups (germinal center B cell-like [GCB]
and activated B cell-like [ABC] DLBCL) were characterized by gene expression profiling (GEP) using cDNA microarray 3, 4 . Due to impracticability to perform microarray analysis on every patient, various immunohistochemical algorithms have been subsequently developed to capture the molecular diversity and stratify patients according to survival [5] [6] [7] [8] . The most widely used method is the Hans algorithm separating DLBCL into germinal-center B cell (GCB) and non-germinal-center B cell (non-GCB) groups by using antibodies against CD10, BCL-6 and MUM-1/IRF-4 9 . In PCNSL, a few small and mostly retrospective studies either failed to observe a prognostic impact of common B cell differentiation markers or revealed contradictory results [10] [11] [12] [13] [14] . Here, we present the analysis of a set of B cell differentiation markers and their prognostic impact in a cohort from G-PCNSL-SG-1, the largest trial ever conducted in PCNSL. as a 4-h i.v. infusion with dose reduction according to creatinine clearence) on day 1 of six 14-day cycles; thereafter, patients were to receive HDMTX plus ifosfamide (1.5 g/m 2 ) on days 3-5 of six 14-day cycles. In those assigned to receive first-line chemotherapy followed by radiotherapy, WBRT was to be given at a total dose of 45 Gy in 1.5 Gy fractions. Patients allocated to first-line chemotherapy without WBRT who had not achieved complete response (CR) to HDMTX-based chemotherapy were given high-dose cytarabine (HDAraC; 2 × 3 g/m 2 on days 1-2 of 22-day cycles).
The study protocol was approved by local institutional review boards or ethics committees.
All participants gave written informed consent.
Immunohistochemical analysis
Immunostaining on paraffin sections was performed centrally at two study reference pathology centers for CD10 (clone 56C6, Leica Biosystems, Newcastle upon Tyne, UK), BCL-6 (clone LN22, Leica Biosystems; clone PG-B6p, Dako, Hamburg, Germany), BCL-2 (clone100/D5 Leica Biosystems; clone 124, Dako) and MUM-1/IRF-4 (clone MUM1p, DAKO) using an automated immunostainer (BondMax™, Leica Biosystems; Benchmark XT, Roche-Ventana, Mannheim, Germany). Antigen retrieval was performed using appropriate
conditions, bound antibodies were made visible employing Bond Polymer Refine DAB, or ultraView Universal DAB detection kit (Roche-Ventana), developed and counterstained using the manufacturer´s protocols and reagents.
Immunohistological labeling of BCL-2, CD10, BCL-6 and MUM-1/IRF-4 was visually analyzed and interpreted according to the methods and cut-off points previously published by
Horn et al. 16 . For BCL-6 staining, tumors with more than 30% positively labeled cells were considered positive. Tumors were further classified to GCB and non-GCB subgroups according to their expression of CD10, BCL-6 and MUM-1/IRF-4 using the methods and cutoff points (>30%) published by Hans et al. 9 . Tumors with CD10 expression, or BCL-6 expression without expression of MUM-1/IRF-4 were defined as GCB. The remaining tumors were classified as non-GCB.
Statistics
Progression-free survival (PFS) was defined as the time from study entry to first progression or death from any cause. Overall survival (OS) was defined as the time from study entry to death. PFS and OS were estimated by the Kaplan-Meier method. Group comparisons were carried out using the log-rank test. Additionally, simple and multiple Cox proportional hazard regression models were calculated, hazard ratios including two-sided 95% limits of confidence were calculated. The variables included in the multiple Cox models were determined by forward and backward variable selection leading to identical models. The median follow-up of all patients studied here was 67.5 months. The median PFS was 10.6 months (95% CI 4.2-17.00), the median OS was 28.9 months (95% CI 18-39.7).
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Prognostic analysis
Among the biologic markers, only BCL-6 expression correlated with shorter PFS and OS:
P=0.047 and P=0.035, respectively ( Fig. 1) . On univariate analysis, the association of BCL-6 was significant for both PFS (HR (Table 2) . All other biologic markers tested did not correlate with outcome. Particularly, classification according to the Hans algorithm revealed no significant difference between GCB and non-GCB subgroups with respect to survival outcome.
Patient characteristics and response to treatment did not differ between BCL-6-positive andnegative patients except for number of brain lesions (Supplementary Table 2 ) with BCL-6 expression significantly being associated with multifocal brain involvement (BCL-6-positive:
33.3% vs BCL-6-negative: 15.7%).
When the impact of commonly accepted clinical risk factors in PCNSL was tested, a . In the present analysis, a correlation between BCL-6 expression and multifocal brain involvement was found. Multifocal brain involvement and inferior survival outcome was a finding in the whole G-PCNSL-SG1 cohort 29 , and was also reported by others 30 .
In our series, we did not observe a significant prognostic difference between the GCB and non-GCB subgroups. This is in line with several smaller studies 12, 14, 18, 25 .
Our study has several limitations that have to be regarded. Although based on the randomized controlled G-PCNSL-SG1 trial, the presented data is a formerly unplanned post hoc analysis of only 23% of all G-PCNSL-SG1 patients with an -unintended -positive selection bias for
analyzed patients. The bias was due to selection of patients on basis of availability of large tumor amount which resulted in higher percentage of patients with <2 tumor lesions and consecutively subtotal or total tumor resection. These factors were associated with better outcome in the total G-PCNSL-SG1 study population 29 and might explain the non-significant, but potentially biologically important trend to a superior prognosis in patients included in our IHC analyses. It remains unclear how this bias might have impacted our findings. A further shortcoming of the study is the number of patients analyzed and the number of events (PFS:
99, OS: 83). Both, although high as compared to previous studies, might have been too low for some outcome differences to become significant, and the multivariate analysis has to be interpreted with caution. Even so the selection of variables was identical with forward and backward methods a change of values in a small number of patients might have led to different models. This may also explain the differences between univariate and multivariate analyses for several factors which showed substantially higher odds ratios in multivariate as compared to univariate analysis (e.g. MSKCC score and multifocal brain involvement in the analysis of OS) .
Most of our patients (74.7%) were treated with HDMTX alone which was the standard firstline treatment regimen at time of study initiation. The type of chemotherapy did not have a significant prognostic impact in our uni-and multivariate analyses, but the number of patients might have been to small. Thus, we cannot exclude that the survival difference between the BCL-6-positive and BCL-6-negative group within our investigation could have been due to the less effective treatment regimen and therefore might not be applicable for patients undergoing an intensified first-line treatment.
In conclusion, our findings confirm an activated B cell like immunophenotype and post-GC origin of PCNSL and indicate BCL-6 expression as a valuable biomarker for inferior
prognosis. In view of the fact that several previous studies reported contradicting results, further prospective studies are necessary to validate our results. 
